What ImmuPharma’s Deals Reveal About Peptide CMC Strategy

Deconstructing ImmuPharma’s Tripartite CMC Blueprint The traditional outsourcing playbook encouraged biotechs to consolidate early-stage programs under one primary vendor to simplify contract…

What ImmuPharma’s Moves Reveal About Peptide CMC Strategy

Deconstructing the Tripartite CMC Ecosystem Building a multi-partner network requires mapping each vendor’s core competency to specific phase-gate deliverables. In the case…

What Lonza’s Margin Hike and ADC Deal Mean…

Decoding the Market Signals: Margin Elevation and the ADC Consolidation Wave To evaluate how big-pharma CDMO strategies impact pipeline execution, developers must…